SCHEMBL5694151

SCHEMBL5694151

CC(C)c1cc(C(C)C)c(S(=O)(=O)n2cnnn2)c(C(C)C)c1

nearest known ligand 0.54

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
FABP4 P15090 6/20 0.54
ALDH1A1 P00352 2/20 0.48
FABP3 P05413 2/20 0.47
FABP5 Q01469 1/20 0.47
PIK3CD O00329 2/20 0.44
PIK3CA P42336 2/20 0.44
PIK3CB P42338 2/20 0.44
PIK3CG P48736 2/20 0.44
PSEN1 P49768 2/20 0.37
PSEN2 P49810 2/20 0.37
APH1B Q8WW43 2/20 0.37
NCSTN Q92542 2/20 0.37
APH1A Q96BI3 2/20 0.37
PSENEN Q9NZ42 2/20 0.37
NOTUM Q6P988 1/20 0.37
EPHX2 P34913 1/20 0.37
GAA P10253 1/20 0.36
GABRA1 P14867 1/20 0.35
GABRB2 P47870 1/20 0.35
TDP1 Q9NUW8 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL9498378 0.79 FABP4 (0.57) FABP4ALDH1A1FABP3FABP5PIK3CD
SCHEMBL5686154 0.76 FABP4 (0.57) FABP4ALDH1A1FABP3FABP5PIK3CD
SCHEMBL5694221 0.71 RAPGEF4 (0.45) ALDH1A1PIK3CDPIK3CAPIK3CBPIK3CG
SCHEMBL29742381 0.71 GAA (0.35) ALDH1A1NOTUMGAA
SCHEMBL9108321 0.70 FABP4 (1.00) FABP4ALDH1A1FABP3FABP5PSEN1
SCHEMBL840945 0.70 FABP4 (1.00) FABP4ALDH1A1FABP3FABP5PSEN1
SCHEMBL1123484 0.70 FABP4 (0.47) FABP4ALDH1A1FABP3FABP5PIK3CD
SCHEMBL8989764 0.68 FABP4 (0.69) FABP4ALDH1A1FABP3FABP5PIK3CD
SCHEMBL4246719 0.68 FABP4 (0.62) FABP4ALDH1A1FABP3FABP5PIK3CD
SCHEMBL2946584 0.68 FABP4 (0.62) FABP4ALDH1A1FABP3FABP5GAA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 60 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-4373071-A RESIN SUPPORTS; GENETIC ENGINEERING CITY OF HOPE RESEARCH INSTITUTE (US) 1983-02-08 US claimed
US-20230123981-A1 4'-O-METHYLENE PHOSPHONATE NUCLEIC ACIDS AND ANALOGUES THEREOF NOVO NORDISK A/S (DK) 2023-04-20 US disclosed
EP-4090665-A1 4'-O-METHYLENE PHOSPHONATE NUCLEIC ACIDS AND ANALOGUES THEREOF Dicerna Pharmaceuticals, Inc. (US) 2022-11-23 EP disclosed
CN-115298192-A 4' -O-methylene phosphonate nucleic acids and analogs thereof 迪克纳制药公司 2022-11-04 CN disclosed
WO-2021146488-A1 4'-O-METHYLENE PHOSPHONATE NUCLEIC ACIDS AND ANALOGUES THEREOF DICERNA PHARMACEUTICALS, INC. (US) 2021-07-22 WO disclosed
US-20060167241-A1 Method for synthesizing cyclic bisdinucleoside MITSUI CHEMICALS, INC. (JP) 2006-07-27 US disclosed
EP-1645561-A1 METHOD OF SYNTHESIZING CYCLIC BISDINUCLEOSIDE Mitsui Chemicals, Inc. (JP) 2006-04-12 EP disclosed
US-5750380-A DNA polymerase mediated synthesis of double stranded nucleic acids CITY OF HOPE RESEARCH INSTITUTE (US) 1998-05-12 US disclosed
US-5583013-A EXPRESSION IN A MICROORGANISM TRANSFORMED WITH A REPLICABLE CLONING VEHICLE; ENCODING DNA IS UNDER THE OPERATIVE CONTROL OF AN EXPRESSION CONTROL REGION GENENTECH, INC. (US) 1996-12-10 US disclosed
US-5548076-A CONDENSING A BLOCKED NUCLEOSIDE BOUND TO A CARRIER GENENTECH, INC. (US) 1996-08-20 US disclosed
US-4366246-A Method for microbial polypeptide expression GENENTECH, INC. (US) 1982-12-28 US disclosed
US-4356270-A Recombinant DNA cloning vehicle GENENTECH, INC. (US) 1982-10-26 US disclosed
EP-0049619-A2 Method for stabilizing and selecting host cells containing recombinant DNA ELI LILLY AND COMPANY (US) 1982-04-14 EP disclosed
US-4310662-A Nucleosidic phosphorylating agent and methods GENENTECH, INC. (US) 1982-01-12 US disclosed
EP-0035454-A2 Desacetylthymosin alpha 1, its process of preparation and its use GENENTECH, INC. (US) 1981-09-09 EP disclosed
EP-0002322-A2 Improved Triester process for the synthesis of oligonucleotides GENENTECH, INC. (US) 1979-06-13 EP disclosed
EP-0001931-A2 Synthetic DNA, process for preparing it and recombinant microbial cloning vehicle containing such DNA GENENTECH, INC. (US) 1979-05-16 EP disclosed
EP-0001930-A2 Method for polypeptide production involving expression of a heterologous gene, recombinant microbial cloning vehicle containing said gene and bacterial culture transformed by said cloning vehicle GENENTECH, INC. (US) 1979-05-16 EP disclosed
EP-0001929-A2 Plasmid for transforming bacterial host to render it capable of polypeptide expression GENENTECH, INC. (US) 1979-05-16 EP disclosed
US-4059592-A COUPLING AGENTS CANADIAN PATENTS AND DEVELOPMENT LIMITED (CA) 1977-11-22 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060167241-A1 Method for synthesizing cyclic bisdinucleoside NSUN2, POLR2H, POLB FABP4 4691/4885ALDH1A1 2897/4885FABP3 4465/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.